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Abstract
Introduction: Type 2 diabetes (T2DM) is a common complex metabolic disorder that has a strong genetic predisposition. Fat mass and 
obesity-associated protein (FTO) is one of the genes of interest to us. Hypomethylation of a CpG site in the FTO gene was significantly 
associated with the risk of T2DM. The aim of the study was to find the answer to the question of whether the polymorphism changes of 
the FTO gene in the pathogenesis of type 2 diabetes are comparable in young, middle aged, and elderly people.
Material and methods: The study involved 282 consecutive patients with type 2 diabetes, who attended a primary healthcare clinic in 
Southern Poland. The study subjects were divided into three groups according to the age at which type 2 diabetes mellitus was diagnosed 
(> 40 years old, 40–60 years old, and > 60 years old). The genotyping of rs9939609, rs1421085, and rs9930506 FTO polymorphisms was 
conducted using TaqManPre-designed SNP Genotyping Assay.
Results: No statistically significant difference was shown between the examined FTO polymorphism (rs9939609, rs1421085, and rs9930506) 
distribution between the subjects diagnosed with diabetes < 40 years , 40–60 years, and > 60 years old.
Conclusions: There were no statistically significant relationships between the different analysed anthropometric and other parameters 
and distribution of examined FTO polymorphisms (rs9939609 , rs1421085, and rs9930506). The age of diabetes was not affect by the tested 
FTO polymorphisms (rs9939609 , rs1421085, and rs9930506). (Endokrynol Pol 2017; 68 (4): 402–406)
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Streszczenie
Wstęp: Cukrzyca typu 2 (T2DM, type 2 diabetes) jest często występującym złożonym zaburzeniem metabolicznym o silnych uwarunkowa-
niach genetycznych. Jednym z genów budzących zainteresowanie badaczy jest gen FTO (fat mass and obesity-associated gene). Hipometylacja 
w pozycji CpG genu FTO wiązała się istotnie z ryzykiem rozwoju T2DM. Celem badania było znalezienie odpowiedzi na pytanie, czy 
polimorfizmy genu FTO w patogenezie cukrzycy typu 2 są podobne u osób w młodym, średnim i podeszłym wieku.
Materiały i metody: Do badania włączono 282 kolejnych chorych na cukrzycę typu 2, którzy zgłaszali się do placówki podstawowej opieki 
zdrowotnej w Polsce południowej. Uczestników badania podzielono na trzy grupy w zależności od wieku w momencie rozpoznania 
cukrzycy typu 2 (> 40 lat, 40–60 lat i > 60 lat). Przeprowadzono genotypowania polimorfizmów rs9939609, rs1421085 i rs9930506 genu 
FTO, używając zestawu TaqMan do genotypowania SNP. 
Wyniki: Nie wykazano statystycznie istotnych różnic w rozkładzie badanych polimorfizmów genu FTO (rs9939609, rs1421085 i rs9930506) 
między osobami, które w momencie rozpoznania cukrzycy miały < 40 lat, 40–60 lat lub > 60 lat.
Wnioski: Nie stwierdzono statystycznie istotnych związków między różnymi analizowanymi parametrami (np. parametrami antropo-
metrycznymi) a rozkładem badanych polimorfizmów genu FTO (rs9939609, rs1421085 i rs9930506). Oceniane polimorfizmy genu FTO 
(rs9939609, rs1421085 i rs9930506) nie wpływały na wiek chorych w momencie rozpoznania cukrzycy. (Endokrynol Pol 2017; 68 (4): 402–406)
Słowa kluczowe: cukrzyca typu 2; gen FTO; wiek 
Introduction
According to the International Diabetes Federation’s 
Diabetes Atlas sixth edition, it was estimated that 382 
million people had diabetes in the year 2013 worldwide, 
and this figure is expected to increase to 592 million in 
2035 [1]. In 2014, 4.9 million deaths were attributable to 
diabetes. It is also the leading cause of blindness, chronic 
kidney disease, and amputation. A substantial effort 
to understand the pathophysiology of type 2 diabetes 
(T2DM) and to develop novel preventive and therapeu-
tic measures for T2DM has been made in recent years [2].
Type 2 diabetes (T2DM) is a common complex meta-
bolic disorder that has a strong genetic predisposition. 
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During the past decade, progress in genetic as-
sociation studies has enabled the identification 
of at least 75 independent genetic loci for T2DM, 
thus allowing a better understanding of the genetic 
architecture of T2DM [2]. Among genes we thing 
about of TCF7L2, PPARG, KCNJ11 and FTO, and iden-
tified novel loci for an association in the intergenic 
region [3–5].
Fat mass and obesity-associated protein (FTO) is one 
of the genes of interest to us. Hypomethylation of a CpG 
site in the FTO gene was significantly associated with 
the risk of T2DM [6]. Fat mass and obesity-associated 
protein, also known as alpha-ketoglutarate-dependent 
dioxygenase (FTO), is an enzyme that in humans is 
encoded by the FTO gene located on chromosome 16. 
As one homolog in the AlkB family of proteins, it is the 
first mRNA demethylase to be identified. The FTO gene 
is widely expressed in both foetal and adult tissues. This 
gene is a nuclear protein of the AlkB-related non-haem 
iron and 2-oxoglutarate-dependent oxygenase super-
family, but the exact physiological function of this gene 
is not known. Other non-heme iron enzymes function 
to reverse alkylated DNA and RNA damage by oxidative 
demethylation. Studies in mice and humans indicate 
a role in nervous and cardiovascular systems and a strong 
association with body mass index, obesity risk, and type 
2 diabetes. The presence of the FTO rs9939609 A allele 
was found to be positively correlated with symptoms of 
metabolic syndrome, including higher fasting insulin, 
glucose, and triglycerides, and lower HDL cholesterol. 
The researchers identified 10 different FTO SNPs in the 
first intron of the gene, which associated with both BMI 
and type-2 diabetes.
The development of type 2 diabetes occurs at dif-
ferent ages. In some patients the disease develops at 
a young age, in some middle age, and in some over 
60 years old. In the pathogenesis of diabetes participate 
environmental as well as genetic factors. It has previ-
ously been shown that the polymorphisms in the gene 
FTO play an important role in the development of 
diabetes. An interesting seem to find an answer to the 
question of whether the genetic effect is the same in 
the young and in the elderly.
Aim
The aim of the study was to find the answer to the 
question of whether the polymorphism changes of 
the FTO gene in the pathogenesis of type 2 diabetes 
are comparable in young, middle aged, and elderly 
people. To find the answer to the above questions 
we estimated three FTO polymorphisms located in 
the first intron of this gene in people diagnosed with 
type 2 diabetes in age < 40 years , between 40 and 60 
years, and > 60 years.
Material and methods
The study involved 282 consecutive patients with type 2 
diabetes, who attended a primary healthcare clinic in 
Southern Poland. Study subjects were divided into three 
groups according to the age at which type 2 diabetes 
mellitus was diagnosed (> 40 years old, 40–60 years 
old, and > 60 years old). The genotyping of rs9939609, 
rs1421085, and rs9930506 FTO polymorphisms was 
conducted with fluorescent-labelled probes using prede-
signed single nucleotide polymorphisms assessment sets 
(TaqManPre-designed SNP Genotyping Assay, Applied 
Biosystems). The distribution of the abovementioned 
polymorphisms are in Hardy-Weinberg equilibrium [7].
Statistical analysis
The data obtained were presented as mean ± standard 
deviation. Normality of data distribution was tested 
with the Shapiro-Wilk test. In the case of non-normal 
distribution, data were normalised with logarithmic 
transformation. Analysis of variances with Tukey post-
hoc test and t-Student test were used in groups for mean 
comparison. Homogeneity of variances was tested with 
the Levene test. Correlations were calculated with the 
Spearman correlation coefficient. All calculations were 
performed with Statistica 9.0 software, and p < 0.05 was 
set as statistically significant.
Results
All patients were divided into three groups. Table I 
presents the main results conducted among subjects.
In the analysed group patients differed in the age 
of diagnosis of diabetes, and diabetes duration. In 
subjects with diabetes diagnosed and BMI > 60 it was 
significantly lower than in the other groups. It was also 
shown that subjects with diabetes diagnosed at > 60 
years old significantly less frequently used insulin than 
people in the other groups, and significantly more often 
used oral treatment than those with diabetes diagnose 
at age 40–60 years. A similar analysis was performed 
for subjects who were carriers of all kinds of FTO 
polymorphisms. There were no significant differences 
between these groups.
Tables II A, B, show the results of determinations 
of FTO polymorphisms rs9939609, rs1421085, and 
rs9930506. 
No statistically significant difference was shown 
between the examined FTO polymorphism (rs9939609, 
rs1421085, and rs9930506) distribution between the 
subjects with diabetes diagnosed at < 40, 40–60, and 
> 60 years. 
There were no statistically significant relation-
ships between the different analysed anthropometric 
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and other parameters and distribution of FTO ex-
amined polymorphisms (rs9939609, rs1421085, and 
rs9930506).
Tables III A, B, and C, D, E, F show the results of 
determination of allele distribution for FTO polymor-
phisms rs9939609, rs1421085, and rs9930506.
No statistically significant difference was shown be-
tween the FTO allele (rs9939609, rs1421085, and rs9930506) 
distribution between the subjects with diabetes diagnosed 
at < 40, 40–60, and > 60 years. We did not find statistically 
significant difference in the FTO allele (rs9939609, rs1421085, 
and rs9930506) distribution between the subjects with 
diabetes diagnosed at < 40, 40–60, and > 60 years, taken 
together.
There were no statistically significant relation-
ships between the different analysed parameters and 
Table I. Basic results obtained in the subjects after the division depending on the age of diagnosis of diabetes
Tabela I. Podstawowe wyniki w zależności od wieku chorych w momencie rozpoznania cukrzycy
Diabetes diagnosis  
at < 40 years old
A
Diabetes diagnosis 
at 40–60 years old
B
Diabetes diagnosis 
at > 60 years old
C
Statistical significance
N 82 100 100
Age [years] 54.2 ± 11.5 62.5 ± 8.6 73.8 ± 7.3 p < 0.05 between each group
Age at diagnosis of diabetes 
[years]
36.9 ± 4.5 51.0 ± 4.7 67.5 ± 6.1 p < 0.05 between each group
Duration of diabetes [years] 17.4 ± 11.0 11.6 ± 8.0 6.3 ± 5.6
p < 0.05 between each group
BMI [kg/m2] 31.5 ± 5.2 30.7 ± 5.0 29.0 ± 4.4 p < 0.05 between groups C and A and B
Hypertension [%] 59 (72%) 75 (75%) 74 (74%) NS
Dyslipidaemia [%] 39 (48%) 61 (61%) 56 (56%) NS
Oral hypoglycaemic drugs [%] 82.9 76.0 89.0 p < 0.05 between groups C and B
Insulin therapy [%] 68.3 55.0 29.0 p < 0.05 between groups C and A and B
Table IIA. Distribution of FTO polymorphism rs9939609 in the study groups
Tabela IIA. Rozkład polimorfizmu rs9939609 genu FTO w badanych grupach
AA AT TT
Diabetes diagnosis at < 40 years 20 (24.30%) 34(41.46%) 28 (34.15%)
Diabetes diagnosis at 40–60 years 24 (24%) 52 (52%) 24 (24%)
Diabetes diagnosis at > 60 years 22 (22% ) 43 (43%) 35 (35%) 
Table IIB. Distribution of FTO polymorphism rs1421085 in the study groups
Tabela IIB. Rozkład polimorfizmu rs1421085 genu FTO w badanych grupach
CC CT TT
Diabetes diagnosis at < 40 years 21 (25.61%) 38 (46.34%) 23 (28.05%)
Diabetes diagnosis at 40–60 years 28 (28%) 50 (50%) 22 (22%)
Diabetes diagnosis at > 60 years 25 (25%) 48 (48%) 27 (27%) 
Table IIC. Distribution of FTO polymorphism rs9930506 in the study groups
Tabela IIC. Rozkład polimorfizmu rs9930506 genu FTO w badanych grupach
AA AG GG
Diabetes diagnosis at < 40 years 28 (34.15%) 32 (39.02%) 22 (26.83%)
Diabetes diagnosis at 40–60 years 21 (21%) 47 (47%) 32 (32%)
Diabetes diagnosis at > 60 years 29 (29%) 47(47%) 24 (24%)
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distribution of examined FTO alleles (rs9939609, 
rs1421085, and rs9930506).
Discussion
The Fat Mass and Obesity (FTO) gene is considered 
as leading obesity and type 2 diabetes [8]. The FTO 
rs9939609 minor allele, the risk allele for obesity, in-
creased the risk of type 2 diabetes, this association 
remaining statistically significant even after adjustment 
for BMI [9]. Similar results were reported in a Scandina-
vian population [10]. In contrast, other studies, despite 
finding a higher type 2 diabetes risk in carriers of the 
risk-allele for obesity, concluded that this association 
disappears when adjusting for BMI and diabetes [11].
A CpG site in the first intron of the FTO gene 
showed small (3.35%) but significant (P 5 0.000021) 
hypomethylation of cases relative to controls. The ef-
fect was independent of the sequence polymorphism 
in the region and persisted among individuals carrying 
the sequence-risk alleles. The odds of belonging to the 
T2DM group increased by 6.1% for every 1% decrease in 
methylation (OR 5 1.061, 95% CI: 1.032–1.090); the odds 
ratio for decrease of 1 standard deviation of methylation 
(adjusted to gender) was 1.5856 (95% CI: 1.2824–1.9606), 
and the sensitivity (area under the curve 5 0.638, 95% 
CI: 0.586–0.690; males 5 0.675, females 5 0.609) was better 
than that of the strongest known sequence variant [6].
In the pathogenesis of diabetes both environmental 
genetic factors take part. In the studies conducted to 
date, 75 independent genetic loci have been identified 
involved in the development of type 2 diabetes [2]. Type 
2 diabetes develops at different ages, with some people 
developing this before the age of 40 years, others be-
tween 40–60 years of age, and some at over 60 years old. 
We asked ourselves whether the FTO polymorphism 
plays an important role in this process.
To find an answer to the above question, we examined 
a group of 282 patients with type 2 diabetes, divided into 
three groups taking into account the age at which they 
were diagnosed with the disease. Patients were assigned 
to the following groups: people with diabetes diagnosed at 
Table IIIA. Allele distribution of FTO polymorphism 
rs9939609 in the study groups
Tabela IIIA. Rozkład alleli z polimorfizmem rs9930506 genu 
FTO w badanych grupach
Allele A (%) Allele T (%)
Diabetes diagnosis at < 40 years 74(44%) 90 (56%)
Diabetes diagnosis at 40–60 years 100 (50%) 100 (50%)
Diabetes diagnosis at > 60 years 87 (43.5%) 113 (56.5%)
Table IIIB. Allele distribution of FTO polymorphism 
rs1421085 in the study groups
Tabela IIIB. Rozkład alleli z polimorfizmem rs1421085 genu 
FTO w badanych grupach
Allele C (%) Allele T (%)
Diabetes diagnosis at < 40 years 80 (47.6% ) 84 (53.25%)
Diabetes diagnosis at 40–60 years 106 (53%) 94 (47%)
Diabetes diagnosis at > 60 years 98 (49%) 102 (51%) 
Table IIIC. Allele distribution of FTO polymorphism 
rs9930506 in the study groups
Tabela IIIC. Rozkład alleli z polimorfizmem rs9930506 genu 
FTO w badanych grupach
Allele A (%) Allele G (%)
Diabetes diagnosis at < 40 years 88 (52.4%) 76 (47.6%)
Diabetes diagnosis at 40–60 years 89 (44.5%) 111 ( 55.5%)
Diabetes diagnosis at > 60 years 105 ( 52.5%) 95 ( 47.5%)
Table IIID. Allele distribution of FTO polymorphism 
rs9939609 in the study groups
Tabela IIID. Rozkład alleli z polimorfizmem rs9939609 genu 
FTO w badanych grupach
Allele A (%) Allele T (%)
Diabetes diagnosis at < 40 years 74 (44%) 90 (56%)
Diabetes diagnosis at 40–60 years  
and diabetes diagnosis  
at > 60 years, together 
187 (46.25%) 213 ( 53.25%)
Table IIIE. Allele distribution of FTO polymorphism 
rs1421085 in the study groups
Tabela IIIE. Rozkład alleli z polimorfizmem rs1421085 genu 
FTO w badanych grupach
Allele C (%) Allele T (%)
Diabetes diagnosis at < 40 years 80 (47.6% ) 84 (53.25 %)
Diabetes diagnosis at 40–60 years 
and diabetes diagnosis  
at > 60 years, together 
204 (51%) 196 (49%)
Table IIIF. Allele distribution of FTO polymorphism 
rs9930506 in the study groups
Tabela IIIF. Rozkład alleli z polimorfizmem rs9930506 genu 
FTO w badanych grupach
Allele A (%) Allele G (%)
Diabetes diagnosis at < 40 years 88 (52.4%) 76 (47.6%)
Diabetes diagnosis at 40–60 years 
and diabetes diagnosis at > 60 
years, together 
194 (48.5%) 206 (51.5%)
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< 40 years of age (n = 82), those with diabetes diagnosed at 
between 40 and 60 years of age (n = 100), and patients with 
diabetes diagnosed at > 60 years of age (n = 100). In all 
patients, we defined the basic anthropometric parameters 
analysed and used for treatment. We have shown that 
there are significant differences between the two groups. 
These differences are presented in Table I. In addition, we 
proved that people with previously diagnosed diabetes at 
the time of the study were younger, diabetes lasted longer 
with them, and their treatment more often included 
insulin. The results are no surprise; the age of diagnosis 
was the inclusion parameter for different groups. More 
frequent use of insulin in patients with diabetes diagnosed 
before the age of 40 years was due to the fact that diabetes 
lasted significantly longer with them. Diabetes mellitus is 
a progressive disease and it leads to systematic damage to 
the beta cells, eventually destroying them, which leads to 
a need for insulin therapy.
In our work, we examined three polymorphisms of 
the FTO gene. We compared the distribution of these 
polymorphisms in patients with diabetes and on this 
basis we have shown that the treatment groups did not 
differ in a statistically significant way from each other in 
relation to the distribution of polymorphisms rs9939609, 
rs1521085, and rs9930506 (Table IIA, 2B, 2C). At the same 
time, we found no statistically significant difference in 
the distributions of allele FTO polymorphisms studied 
between the two groups (Table IIIA, 3B, 3C). 
Comparing the group of people with diabetes dia-
gnosed between the ages of 40 and 60 years old and 
the group in which diabetes was diagnosed at 60 years 
of age, we also noted significant differences in the dis-
tribution of polymorphisms of the FTO gene, as well 
as alleles of these polymorphisms (Table IIID, 3E, 3F).
In our work we do not have considered, however, 
whether the FTO gene is involved in the pathogenesis of 
type 2 diabetes, but only over whether the importance of 
this gene in the pathogenesis of type 2 diabetes is higher 
in patients whose diabetes was diagnosed at a younger 
age (< 40 years old) as compared to diabetic patients dia-
gnosed at age 40–60 years or over 60 years. The survey 
showed that the studied FTO polymorphisms have no 
impact on the age at which diabetes develops.
Conclusions
1. No significant relationships between the different 
analysed anthropometric and other parameters 
and distribution of examined FTO polymorphisms 
(rs9939609, rs1421085, and rs9930506).
2. The age of diabetes was not affect by the tested 
FTO polymorphisms (rs9939609, rs1421085, and 
rs9930506).
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